Sentences with phrase «cell lung cancer resulted»

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Not exact matches

«Our study results suggest a new drug cocktail that is effective in both human lung cancer cell lines and fly models,» says Cagan.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

«Our laboratory results are promising and certainly provide encouragement to test this treatment clinically in patients with small cell lung cancer.»

Their results will help diseased cells to be characterised more exactly compared to healthy cells — which will enable a better understanding of cancer, lung diseases and heart diseases to be developed.

«Our results suggest that administering p38 inhibitors to certain patients with advanced stages of colon cancer or with established metastases could be counterproductive and may enhance cell acquisition of lung colonization potential,» says Gomis.

As a result, the mice had twice as many cancer cells zipping through their bloodstream and in their lungs compared with mice not treated with paclitaxel.

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.

A randomized, phase II trial showed improved progression - free survival in small - cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.

Two clinical trials that used antibodies to block PD - 1 and PD - L1, a related molecule that binds to PD - 1, resulted in significant and long lasting responses against melanoma skin cancer, renal cell (kidney) cancer, and lung cancer.

The experimental metastasis assay we detail here includes tail - vein injection of cancer cells into the mouse and determination of the resulting secondary organ colonization, primarily in the lung, 10 d post dosing.

The result was a highly selective drug they named SBI - 0206965, which successfully killed a number of cancer cell types, including human and mouse lung cancer cells and human brain cancer cells, some of which were previously shown to be particularly reliant on cellular recycling.

«The TAILOR study draws out attention to the fact that outcomes are poor in second - line treatment of non — small - cell lung cancer, with our available treatments resulting in median progression - free survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in Melbcancer, with our available treatments resulting in median progression - free survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in MelbCancer Centre in Melbourne.

Paclitaxel by either 1 - hour or 24 - hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.

If clinical trials of anti-PD-1 continue to show promising results, cancer patients may soon have access to another powerful immunotherapy for the treatment of numerous cancers, including melanoma, non-small cell lung cancer, and other solid tumors.

Detection of immune cell checkpoint and functional markers in the lung TME: The field of cancer immunotherapy continues to expand rapidly over recent years, with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches.

Finally, to determine whether LARP7 KD also results in an increase in breast cancer metastasis in vivo, the T47D control or shLARP7 - 2 cells were injected intravenously into the nude mice, and lung metastasis was examined 12 weeks later.

The plaintiff claimed that the defendant misread the 1/15/10 chest x-ray resulting in a 3 year delay in diagnosis of non-small cell lung cancer.